VR Logo

MacroGenics Inc. (MGNX) download report


Healthcare | Biotechnology & Pharma Research

MacroGenics Inc. (MGNX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.

IPO Date: 10-Oct-2013

Pres, CEO & Director: Dr. Scott Koenig M.D., Ph.D.

Sr. VP, CFO & Corp. Sec.: Mr. James Karrels

Listing: NASDAQ: MGNX

Country: United States

Headquarters: Rockville, MD

Website: https://www.macrogenics.com

Key Facts

Market cap: $187.07 Mln

Revenue (TTM): $70.25 Mln

Earnings (TTM): $-217.29 Mln

Cash: $183.99 Mln

Total Debt: $24.35 Mln

Insider's Holding: 2.60%

Liquidity: Low

52 Week range: $2.13 - 29.16

Shares outstanding: 61,333,500

10 Years Aggregate:

  • CFO: $-639.68 Mln
  • EBITDA: $-720.70 Mln
  • Net Profit: $-783.62 Mln

Stock Performance

Time Period MacroGenics (MGNX) S&P BSE Sensex S&P Small-Cap 600
YTD-81.00-9.18-18.78
1 month-12.86-4.78-8.00
3 months-65.38-9.66-13.65
1 Year-88.640.81-17.19
3 Years-43.5710.336.10
5 Years-29.5011.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year MacroGenics (MGNX) S&P Small-Cap 600 S&P BSE Sensex
2021-29.7925.2721.99
2020110.119.5715.75
2019-14.3320.8614.38
2018-33.01-9.705.87
2017-7.0511.7327.91
2016-34.0024.741.95
2015-11.69-3.36-5.03